Rigel Pharmaceuticals, Inc.
NASDAQCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Raul R. Rodriguez
- Full Time Employees
- 173
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 611 Gateway Boulevard South San Francisco CA United States of America 94080
- IPO Date
- Nov 29, 2000
- CIK
- 0001034842
- Website
- rigel.com
- Similar Companies
- Business
- Rigel Pharmaceuticals, Inc. operates as a biotechnology enterprise dedicated to identifying and advancing small molecule therapeutics for hematologic conditions, various cancers, and uncommon immune system diseases. The company offers TAVALISSE (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor approved for adult patients with chronic immune thrombocytopenia who have shown an inadequate response to prior treatments. Fostamatinib is also being explored in a Phase 1 study for sickle cell disease, supported by the National Institutes of Health. In its commercial portfolio, Rigel includes REZLIDHIA (olutasidenib) for relapsed or refractory acute myeloid leukemia featuring IDH1 mutations, and GAVRETO (pralsetinib), which addresses metastatic RET fusion-positive non-small cell lung cancer and certain advanced thyroid cancers. The pipeline also features R289, an oral interleukin receptor associated kinase 1/4 inhibitor, currently undergoing a Phase 1b clinical trial in patients with relapsed or refractory lower-risk myelodysplastic syndrome, having recently initiated its dose expansion phase. This candidate has received both Orphan Drug Designation and Fast Track designation from the FDA. Furthermore, R552, a receptor-interacting serine/threonine-protein kinase 1 inhibitor, is progressing into Phase 2 development for autoimmune and inflammatory indications, including psoriasis, under a collaborative arrangement with Eli Lilly and Company, which also oversees the advancement of CNS-penetrant RIPK1 inhibitors. Rigel Pharmaceuticals maintains strategic licensing and collaboration agreements, including those for TAVALISSE with Kissei Pharmaceutical Co., Ltd. for markets in Asia, and with Grifols, S.A. for commercialization across Europe and Turkey. The company, which commenced operations in 1996, is headquartered in South San Francisco, California. Rigel reported strong financial performance in 2025, with an updated full-year revenue guidance reflecting significant growth driven by its product sales.
Company News
Rigel to Participate in Upcoming September Investor Conferences
18,800 Shares in Rigel Pharmaceuticals, Inc. $RIGL Bought by Canada Pension Plan Investment Board
Connor Clark & Lunn Investment Management Ltd. Buys Shares of 49,096 Rigel Pharmaceuticals, Inc. $RIGL
Rigel Announces Availability of VEPPANU™ (vepdegestrant) for Patients with ER+/HER2-, ESR1-Mutated Advanced or Metastatic Breast Cancer
Rigel Pharmaceuticals: A Four-Drug Company With A Clinical Catalyst Ahead
Rigel Pharmaceuticals: The Easy Money Has Been Made (Rating Downgrade)
Rigel Pharmaceuticals, Inc. (RIGL) Q2 2026 Earnings Call Transcript
Rigel Pharmaceuticals Q2 Earnings Call Highlights
Rigel Pharmaceuticals (RIGL) Q2 Earnings Miss Estimates
Rigel Reports Second Quarter 2026 Financial Results
Rigel Announces Conference Call and Webcast to Report Second Quarter 2026 Financial Results
Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Rigel Appoints Board Member Alison L. Hannah, M.D.
A Look At The Transformation Around Rigel Pharmaceuticals
Rigel Announces Closing of Licensing Agreement for VEPPANU™ (vepdegestrant)
Rigel to Present at the Jefferies Global Healthcare Conference
Rigel Announces Oral and Poster Presentations at the 2026 ASCO Annual Meeting and EHA2026 Congress
Rigel to Present at the 2026 RBC Capital Markets Global Healthcare Conference
Rigel Pharmaceuticals, Inc. (RIGL) M&A Call Transcript
Rigel Pharmaceuticals Inks Breast Cancer Drug Deal With Arvinas, Pfizer